FibroGen (FGEN) Stock Price, News & Analysis

-0.07 (-6.14%)
(As of 04/23/2024 ET)
Today's Range
50-Day Range
52-Week Range
1.35 million shs
Average Volume
2.47 million shs
Market Capitalization
$105.68 million
P/E Ratio
Dividend Yield
Price Target

FibroGen MarketRank™ Stock Analysis

Analyst Rating
1.75 Rating Score
1,488.8% Upside
$17.00 Price Target
Short Interest
5.65% of Float Sold Short
Dividend Strength
Upright™ Environmental Score
News Sentiment
0.89mentions of FibroGen in the last 14 days
Based on 3 Articles This Week
Insider Trading
Acquiring Shares
$95,500 Bought Last Quarter
Proj. Earnings Growth
From ($1.09) to ($0.06) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.43 out of 5 stars

Medical Sector

106th out of 910 stocks

Pharmaceutical Preparations Industry

35th out of 426 stocks

FGEN stock logo

About FibroGen Stock (NASDAQ:FGEN)

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.

FGEN Stock Price History

FGEN Stock News Headlines

FibroGen, Inc. (NASDAQ:FGEN) Short Interest Down 6.1% in March
top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)
AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.
FibroGen (FGEN) Gets a Sell from Goldman Sachs
top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)
AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.
FibroGen Appoints Deyaa Adib As CMO
FibroGen Full Year 2023 Earnings: Misses Expectations
Here's what Wall Street expects from FibroGen's earnings report
FGEN Jan 2026 1.000 call
FibroGen's Earnings Outlook
FibroGen Stock (NASDAQ:FGEN) Insider Trades
First Gen Corp FGEN
FGEN Jan 2025 3.500 call
See More Headlines
Receive FGEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for FibroGen and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
4 Analysts


Net Income
Net Margins
Pretax Margin


Sales & Book Value

Annual Sales
$147.75 million
Book Value
($1.87) per share


Free Float
Market Cap
$111.61 million
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

  • Mr. Thane WettigMr. Thane Wettig (Age 59)
    CEO & Director
    Comp: $807.35k
  • Mr. Juan Graham (Age 47)
    Senior VP & CFO
    Comp: $991.76k
  • Ms. Christine L. Chung (Age 56)
    Senior Vice President of China Operations
    Comp: $1.27M
  • Dr. Barry A. Berkowitz Ph.D.
  • Dr. John J. Hunter Ph.D. (Age 61)
    Chief Scientific Officer
  • David DeLucia
    Vice President of Corporate FP&A and Investor Relations
  • Mr. Michael D. Lowenstein J.D.
    Ph.D., Chief Legal Officer
  • Ms. Tricia Stewart
    Chief People Officer
  • Mr. Kirk A. Christoffersen MBA (Age 55)
    Chief Business Officer
  • Dr. Rahul Rajan Kaushik Ph.D.
    Senior Vice President of Pharmaceutical Development, Technical Operations & Manufacturing

FGEN Stock Analysis - Frequently Asked Questions

Should I buy or sell FibroGen stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for FibroGen in the last twelve months. There are currently 1 sell rating and 3 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "reduce" FGEN shares.
View FGEN analyst ratings
or view top-rated stocks.

What is FibroGen's stock price target for 2024?

4 brokers have issued 12-month price objectives for FibroGen's stock. Their FGEN share price targets range from $2.00 to $32.00. On average, they expect the company's share price to reach $17.00 in the next year. This suggests a possible upside of 1,488.8% from the stock's current price.
View analysts price targets for FGEN
or view top-rated stocks among Wall Street analysts.

How have FGEN shares performed in 2024?

FibroGen's stock was trading at $0.8863 at the start of the year. Since then, FGEN shares have increased by 20.7% and is now trading at $1.07.
View the best growth stocks for 2024 here

Are investors shorting FibroGen?

FibroGen saw a decline in short interest in March. As of March 31st, there was short interest totaling 5,190,000 shares, a decline of 6.1% from the March 15th total of 5,530,000 shares. Based on an average trading volume of 2,740,000 shares, the short-interest ratio is presently 1.9 days. Approximately 5.7% of the shares of the company are short sold.
View FibroGen's Short Interest

When is FibroGen's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024.
View our FGEN earnings forecast

How were FibroGen's earnings last quarter?

FibroGen, Inc. (NASDAQ:FGEN) issued its earnings results on Monday, February, 26th. The biopharmaceutical company reported ($0.57) EPS for the quarter, missing analysts' consensus estimates of ($0.42) by $0.15. The biopharmaceutical company had revenue of $27.14 million for the quarter, compared to analyst estimates of $40 million.

What other stocks do shareholders of FibroGen own?
When did FibroGen IPO?

FibroGen (FGEN) raised $146 million in an IPO on Friday, November 14th 2014. The company issued 8,100,000 shares at $18.00 per share. Goldman Sachs, Citigroup and Leerink Partners served as the underwriters for the IPO and RBC Capital Markets, Stifel and William Blair were co-managers.

Who are FibroGen's major shareholders?

FibroGen's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Accel Wealth Management (0.04%). Insiders that own company stock include Benjamin Cravatt, Christine Chung, Enrique A Conterno, James A Schoeneck, Jeffrey William Henderson, Juan Graham, Mark Eisner, Pat Cotroneo, Thane Wettig and Thomas F Kearns Jr.
View institutional ownership trends

How do I buy shares of FibroGen?

Shares of FGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:FGEN) was last updated on 4/23/2024 by Staff

From Our Partners